What do the numbers say about Ipca Laboratories Ltd. (IPCALAB)? Here's a look at its financials, valuation, and ownership data.
Ipca Laboratories Revenue Trend
For FY2025, Ipca Laboratories Ltd. recorded revenue of ₹9,032 Cr. That's 15.4% higher than the ₹7,830 Cr it brought in during FY2024.
A 11.1% CAGR over 10 years puts Ipca Laboratories Ltd. in solid growth territory. The top line went from ₹3,142 Cr to ₹9,032 Cr in that span.
In terms of scale, Ipca Laboratories Ltd.'s ₹9,032 Cr in annual revenue positions it as a mid-sized pharmaceuticals company.
It's been 9 years of continuous revenue growth for Ipca Laboratories Ltd. — a pattern worth noting.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹9,032 Cr | +15.4% |
| FY2024 | ₹7,830 Cr | +22.9% |
| FY2023 | ₹6,370 Cr | +8.0% |
| FY2022 | ₹5,896 Cr | +8.8% |
| FY2021 | ₹5,420 Cr | — |
View Ipca Laboratories Ltd.'s full 10-year revenue trend with CAGR analysis →
Ipca Laboratories Profitability
On the profitability front, Ipca Laboratories Ltd. did well — net income rose 50.2% to ₹785 Cr from ₹523 Cr a year earlier.
Margins tell a good story: net profit margin moved up to 8.7% from 6.7%.
The diluted EPS figure moved up to ₹29.08 in FY2025, against ₹21.57 posted in FY2024.
Is Ipca Laboratories Undervalued
Using the P/E Ratio methodology, the calculated intrinsic value comes to ₹1,384.
Ipca Laboratories Ltd. shares are currently trading at ₹1,554.70.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹1,384 | 11.0% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Ipca Laboratories Ltd. with detailed assumptions →
Ipca Laboratories Shareholding Pattern
Promoter holding has remained stable at 44.7% over the past 4 quarters, indicating confidence in the company's direction.
On the foreign institutional side, the holding is 10.6% as of March 2026 — down from 10.7%.
On the domestic institutional side, the holding is 37.5% as of March 2026 — up from 36.2%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 44.7% | 10.6% | 37.5% | 7.2% |
| Dec 2025 | 44.7% | 10.6% | 37.3% | 7.3% |
| Sep 2025 | 44.7% | 10.4% | 36.8% | 8.1% |
| Jun 2025 | 44.7% | 10.7% | 36.2% | 8.4% |
Track quarterly shareholding changes for Ipca Laboratories Ltd. →
Ipca Laboratories Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹117.61B at the end of FY2025, up 5.9% from ₹111.01B a year earlier.
Property, Plant & Equipment is the largest block at 38.0%, followed by Inventories at 21.8% and Receivables at 15.9%.
Equity makes up 71.3% of liabilities and equity, with debt at 11.6% and operating liabilities at 17.1%. Over the year, debt is down 5.3% and equity is up 8.6%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 9.31B |
| Receivables | 18.74B |
| Inventories | 25.60B |
| Property, Plant & Equipment | 44.67B |
| Investments | 2.16B |
| Intangibles & Goodwill | 2.03B |
| Other Assets | 15.10B |
| Category | Value |
|---|---|
| Equity | 83.88B |
| Short-term Debt | 7.69B |
| Long-term Debt | 5.94B |
| Trade Payables | 8.46B |
| Other Liabilities | 11.63B |
Ipca Laboratories Investment Snapshot
Pulling it all together, here's what the numbers say about Ipca Laboratories Ltd. (IPCALAB) heading into the next fiscal year.
Revenue of ₹9,032 Cr in FY2025, up 15.4% year-over-year.
Long-term revenue has been compounding at 11.1% annually over 10 years.
The company is profitable, with a net margin of 8.7% and net income of ₹785 Cr.
The P/E Ratio model implies 11.0% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Ipca Laboratories Ltd..